All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The path to market for Genelabs Technologies Inc.'s lupus drug Prestara narrowed this week when another Phase III trial failed to meet the primary endpoint. (BioWorld Today)
